Wellington Management Group LLP Trims Stock Position in Encompass Health Co. (NYSE:EHC)

Wellington Management Group LLP lowered its stake in Encompass Health Co. (NYSE:EHC) by 22.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,030,442 shares of the company’s stock after selling 1,189,732 shares during the period. Wellington Management Group LLP’s holdings in Encompass Health were worth $372,211,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Miracle Mile Advisors LLC increased its stake in Encompass Health by 3.0% in the 4th quarter. Miracle Mile Advisors LLC now owns 3,835 shares of the company’s stock valued at $354,000 after buying an additional 112 shares during the period. US Bancorp DE increased its stake in shares of Encompass Health by 9.6% during the fourth quarter. US Bancorp DE now owns 1,380 shares of the company’s stock worth $127,000 after acquiring an additional 121 shares during the period. Signaturefd LLC raised its holdings in Encompass Health by 21.6% during the fourth quarter. Signaturefd LLC now owns 704 shares of the company’s stock worth $65,000 after purchasing an additional 125 shares in the last quarter. CBIZ Investment Advisory Services LLC lifted its position in Encompass Health by 38.7% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock valued at $42,000 after purchasing an additional 127 shares during the period. Finally, MassMutual Private Wealth & Trust FSB boosted its holdings in Encompass Health by 87.8% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after purchasing an additional 137 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Insider Transactions at Encompass Health

In related news, CAO Andrew L. Price sold 5,042 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total transaction of $495,578.18. Following the sale, the chief accounting officer now owns 69,164 shares in the company, valued at approximately $6,798,129.56. This trade represents a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.10% of the company’s stock.

Encompass Health Stock Down 0.0 %

EHC stock opened at $101.27 on Wednesday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. Encompass Health Co. has a 12 month low of $78.53 and a 12 month high of $104.55. The firm has a market capitalization of $10.20 billion, a PE ratio of 22.71, a P/E/G ratio of 2.31 and a beta of 0.92. The company’s 50 day simple moving average is $98.92 and its 200-day simple moving average is $97.58.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. Equities analysts expect that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Tuesday, April 1st will be paid a dividend of $0.17 per share. The ex-dividend date is Tuesday, April 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.67%. Encompass Health’s dividend payout ratio is currently 15.25%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on EHC shares. Royal Bank of Canada reissued an “outperform” rating and set a $110.00 target price on shares of Encompass Health in a research note on Tuesday, February 11th. KeyCorp raised their target price on Encompass Health from $117.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, February 10th. William Blair restated an “outperform” rating on shares of Encompass Health in a research report on Friday, February 7th. Barclays increased their price target on shares of Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Finally, StockNews.com upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, February 15th. Ten equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $107.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.